Department of Chemistry and Applied Biosciences, ETH Zurich, Vladimir Prelog Weg 4, 8093, Zurich, Switzerland.
Current address: Department of Paediatrics, Medical Sciences Division, University of Oxford, OX1 3QX, Oxford, UK.
ChemMedChem. 2021 Nov 19;16(22):3391-3395. doi: 10.1002/cmdc.202100388. Epub 2021 Sep 8.
Single-stranded phosphorothioate (PS) oligonucleotide drugs have shown potential for the treatment of several rare diseases. However, a barrier to their widespread use is that they exhibit activity in only a narrow range of tissues. One way to circumvent this constraint is to conjugate them to cationic cell-penetrating peptides (CPPs). Although there are several examples of morpholino and peptide nucleic acids conjugated with CPPs, there are noticeably few examples of PS oligonucleotide-CPP conjugates. This is surprising given that PS oligonucleotides presently represent the largest class of approved RNA-based drugs, including Nusinersen, that bears the 2'-O-methoxyethyl (MOE)-chemistry. In this work, we report a method for in-solution conjugation of cationic, hydrophobic peptides or human serum albumin to a 22-nucleotide MOE-PS oligonucleotide. Conjugates were obtained in high yields and purities. Our findings pave the way for their large-scale synthesis and testing in vivo.
单链硫代磷酸酯 (PS) 寡核苷酸药物已显示出在治疗几种罕见疾病方面的潜力。然而,它们在广泛应用中面临的一个障碍是,它们仅在狭窄的组织范围内发挥作用。规避这一限制的一种方法是将它们与阳离子穿透肽 (CPP) 缀合。尽管有几种与 CPP 缀合的吗啉代和肽核酸的例子,但 PS 寡核苷酸-CPP 缀合物的例子明显较少。这令人惊讶,因为 PS 寡核苷酸目前代表了最大的一类已批准的基于 RNA 的药物,包括含有 2'-O-甲氧基乙基 (MOE)-化学的 Nusinersen。在这项工作中,我们报告了一种在溶液中用阳离子、疏水性肽或人血清白蛋白与 22 个核苷酸 MOE-PS 寡核苷酸缀合的方法。缀合物以高产率和高纯度获得。我们的发现为它们的大规模合成和体内测试铺平了道路。